Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.
Adams SF, Gimotty PA, Rutledge TL, O'Malley DM et al. • Nature communications
(2026)
PMC
PMC Public Access (View-Only)
DOI:
10.1038/s41467-026-78395-y
PMC: PMC13737286